🍄 Quick Summary Ibogaine is a plant-derived psychedelic from the West African Tabernanthe iboga shrub that has shown remarkable results for opioid addiction, PTSD, and traumatic brain injury in early research. It remains Schedule I in the United States, but Texas has allocated $50 million for clinical research, Stanford published landmark veteran data in 2024–2025, […]
Category Archives: Science and Reserach
🍄 Quick Summary Microdosing psilocybin for anxiety is the most common reason people start the practice — and the evidence is genuinely encouraging. Large observational studies show consistent anxiety and stress reductions in microdosers. Controlled trials are more cautious. Dose, protocol, and product quality determine most of the outcome. Introduction Microdosing psilocybin for anxiety is […]
🍄 Quick Summary Lion’s mane mushroom for brain health is backed by real science — but the evidence is more nuanced than most supplement labels suggest. It contains unique compounds that stimulate nerve growth factor production in the brain, with the strongest clinical evidence in older adults and people with mild cognitive impairment. Results in […]
🍄 Quick Summary Psychedelic therapy in 2026 costs between $1,500 and $12,000 depending on the compound, provider, and location — and insurance covers almost none of it. Psilocybin therapy in Oregon or Colorado runs $3,500–$5,000 per treatment plan. Ketamine is the most accessible at $2,400–$4,800 for a full course. Clinical trials offer free access for […]
🍄 Quick Summary The Department of Veterans Affairs is now funding psilocybin and MDMA-assisted therapy trials across nine VA facilities — the first time in over 50 years the VA has invested in psychedelic research. Early data shows psilocybin reduces PTSD symptoms by disrupting trauma circuits in the brain. This guide covers what the science […]
🍄 Quick Summary Psilocybin disrupts the brain’s default mode network, triggers neuroplasticity, and produces therapeutic effects that persist weeks after a single dose. Studies from Johns Hopkins, Nature (2024), and Cell (2026) now confirm it as one of the most neurologically significant compounds ever studied — with real clinical implications for depression, anxiety, and addiction. […]






